Taiho Oncology, Inc
101 Carnegie Center, Suite 101
Princeton, NJ 08540
Taiho Oncology, Inc. works urgently to discover and develop innovative cancer treatments. As cancer evolves, we evolve with it—bringing novel technology to cornerstone chemotherapies, while at the same time optimizing new targeted agents. Advanced technology, dedicated investigators, and incomparable facilities—these vast resources empower us to redefine the way the world treats cancer. It’s our work; it’s our passion; it’s our legacy.
CHALLENGING CANCER IS OUR LEGACY
Born from Taiho Pharmaceutical’s legacy of developing and marketing leading anti-metabolite cancer drugs, Taiho Oncology is focused on smarter cornerstone anti-metabolites as well as on targeted small molecule inhibitors.
Taiho Pharmaceutical engages in the research, development, and manufacturing of pharmaceutical products in the fields of oncology, allergy/immunology, and urology. The company also offers nutrient tonic and crude drug gastrointestinal remedy products.
Since releasing Futraful (tegafur) in 1974, Taiho Pharmaceutical has been a pioneer in the field of oral anti-cancer agents with products including UFT (tegafur uracil) and TS-1 Capsules (tegafur, gimeracil, oteracil potassium).
Leveraging its findings during the development of IPD (suplatast tosilate), Taiho Pharmaceutical has begun developing anti-allergic drugs with new mechanisms of action.
Based on the development of BUP-4 (propiverine hydrochloride), Taiho Pharmaceutical is proceeding with research and development in new types of treatments for urinary incontinence.
A MEMBER OF OTSUKA HOLDINGS
As a member of the Otsuka Group, Taiho Oncology, Inc. is part of a group of over 150 companies that are dedicated to improving global health and well-being. Together, we have a long history of providing comprehensive healthcare solutions, ranging from diagnosis to the treatment of disease.
For more information, visit www.otsuka.com/en.